Glofitamab with GemOx for diffuse large B-cell lymphoma

Abstract

1 Abramson and colleagues acknowledge that “due to the evolving global treatment standards for CAR [chimeric antigen receptor] T-cell therapies during the period of study enrolment, patients who were candidates for CAR T-cell therapy at study entry were not excluded from STARGLO”. For these patients at high risk of second-line failure, CAR T-cell therapy is approved irrespective of transplant eligibility and has shown curative potential, as evidenced by a plateau in the survival curves. 1,2 The presented Kaplan–Meier analyses illustrate outcomes for treatment groups but not for relevant risk factors within each group. PB reports research funding from Incyte, Merck Sharp & Dohme, Miltenyi Biotec, and Takeda Oncology; consulting fees from Bristol Myers Squibb/Celgene, Gilead Kite, Merck Sharp & Dohme, Miltenyi Biotec, Roche, and Takeda Oncology; honoraria for lectures or presentations from AstraZeneca, AbbVie, Bristol Myers Squibb/Celgene, Gilead Kite, Incyte, Merck Sharp & Dohme, Miltenyi Biomedicine, Roche, Beigene, and Takeda Oncology; and travel grants from Bristol Myers Squibb/Celgene, Gilead Kite, Incyte, Merck Sharp & Dohme, Miltenyi Biotec, Roche, and Takeda Oncology. BvT reports research funding from Esteve, Merck Sharp & Dohme, Novartis, and Takeda; consulting fees from AbbVie, Allogene, Amgen, Bristol Myers Squibb/Celgene, Cerus, Gilead Kite, Incyte, IQVIA, Janssen-Cilag, Lilly, Merck Sharp & Dohme, Miltenyi, Novartis, Noscendo, Pentixapharm, Pfizer, Pierre Fabre, Qualworld, Regeneron, Roche, Serb, Sobi, and Takeda; honoraria for lectures or presentations from AbbVie, AstraZeneca, Bristol Myers Squibb/Celgene, Gilead Kite, Incyte, Janssen-Cilag, Lilly, Merck Sharp & Dohme, Novartis, Roche, Serb, and Takeda; travel grants from AbbVie, AstraZeneca, Gilead Kite, Janssen-Cilag, Lilly, Merck Sharp & Dohme, Pierre Fabre, Roche, Takeda, and Novartis; and participation on steering committees for Regeneron and Takeda.